Comparison of Ropivacaine 0.2% and Lidocaine 0.5% for Intravenous Regional Anesthesia in Volunteers

Abstract

In this study, volunteers received lidocaine 0.5% or ropivacaine 0.2% for IV regional anesthesia on two study days. Ropivacaine and lidocaine provided similar surgical conditions. However, after release of the distal tourniquet, prolonged sensory blockade and fewer central nervous system side effects were observed with ropivacaine.

Bilateral forearm intravenous regional anesthesia with prilocaine for botulinum toxin treatment of palmar hyperhidrosis

“…34 Ropivacaine also has a low systemic toxicity, and offers a long-lasting sensory blockade. 35 This could be an advantage in hand surgery, but is of no benefit for treatment of hyperhidrosis as the BTX injection procedure is too short. Bupivacaine is too cardiotoxic to be recommended for IVRA.…”

Comparison of ropivacaine 0.2% and 0.25% with lidocaine 0.5% for intravenous regional anesthesia

“…A dose of 80 mg of ropivacaine 0.2% was considered appropriate for comparison with 200 mg of lidocaine 0.5% [1]. However, the optimal concentration of ropivacaine for IVRA has not yet been determined.…”

“…Currently, there is no recommended dose for ropivacaine in IVRA. The use of an equipotent dose of ropivacaine has been suggested [1,3]. The potency ratio used in the current study was assumed as 2:0.8 and 2:1 for ropivacaine 0.2% and 0.25%, respectively, versus lidocaine 0.5%.…”

“…Ropivacaine was introduced as a new amide local anesthetic that was structurally related to bupivacaine with a duration of action almost as long as for bupivacaine; however, it has lower central nervous system (CNS) and cardiovascular toxicity compared with bupivacaine, presumably because it is a pure s-enantiomer [1]. In several volunteer studies, intravenous (IV) ropivacaine 0.2% for IV regional anesthesia (IVRA) was as effective as lidocaine 0.5% [1,2].…”

“…In several volunteer studies, intravenous (IV) ropivacaine 0.2% for IV regional anesthesia (IVRA) was as effective as lidocaine 0.5% [1,2]. Clinical use of ropivacaine 0.2% was established for IVRA in one study.…”